Ascendis Pharma Slides as Investors Weigh Novo Rights Reversion Despite Buyback

Ascendis Pharma A/S (ASND) is down 10.9% today. Here is some analysis on what might have caused this price movement. ([investors.ascendispharma.com](https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-regain-rights-transconr-technology-metabolic-and))

Analysis: The most likely driver is investor disappointment over the end of Ascendis’ metabolic and cardiovascular collaboration, which sends rights to the once-monthly TransCon semaglutide program back to Ascendis but also removes the backing of a larger partner. A same-day analyst downgrade tied to that partnership shift appears to have reinforced the negative reaction, even though the company also announced a $400 million share repurchase program. ([investors.ascendispharma.com](https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-regain-rights-transconr-technology-metabolic-and))

Details:

Ascendis said all rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon semaglutide, will revert to the company after the collaboration termination. ([investors.ascendispharma.com](https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-regain-rights-transconr-technology-metabolic-and))

The company said neither side will have continuing financial obligations to the other after the termination, which may have led investors to reassess the program’s strategic value and development path. ([investors.ascendispharma.com](https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-regain-rights-transconr-technology-metabolic-and))

Ascendis plans to advance multiple new programs itself, including the obesity and type 2 diabetes candidate, but that also implies more execution and funding responsibility will sit with Ascendis. This could be because investors prefer near-term certainty from a large-partner arrangement. ([investors.ascendispharma.com](https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-regain-rights-transconr-technology-metabolic-and))

Management also authorized a share repurchase of up to $400 million, but that supportive capital action was not enough to offset the market’s focus on the collaboration change. ([investors.ascendispharma.com](https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-announces-planned-400-million-share-repurchase-program))

Sources:

Ascendis Pharma, Investing.com, OpenAI Finance

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ASND Insider Trading Activity

$ASND insiders have traded $ASND stock on the open market 11 times in the past 6 months. Of those trades, 9 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $ASND stock by insiders over the last 6 months:

MADS BODENHOFF (SVP & PAO) sold 3,000 shares for an estimated $810,570
JEAN JACQUES BIENAIME has made 7 purchases buying 2,900 shares for an estimated $699,336 and 0 sales.
SCOTT THOMAS SMITH (EVP & Chief Financial Officer) has made 2 purchases buying 350 shares for an estimated $77,730 and 0 sales.
LARS HOLTUG sold 236 shares for an estimated $62,334

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive ASND Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$ASND Hedge Fund Activity

We have seen 177 institutional investors add shares of $ASND stock to their portfolio, and 184 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 5,674,622 shares (+525.3%) to their portfolio in Q2 2026, for an estimated $1,513,535,179
BLACKROCK, INC. added 1,550,779 shares (+234.6%) to their portfolio in Q2 2026, for an estimated $413,623,774
ARTISAN PARTNERS LIMITED PARTNERSHIP removed 596,164 shares (-18.5%) from their portfolio in Q2 2026, for an estimated $159,008,862
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. removed 556,427 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $148,410,209
CITADEL ADVISORS LLC removed 519,516 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $118,828,894
STATE STREET CORP added 426,635 shares (+488.5%) to their portfolio in Q2 2026, for an estimated $113,792,087
PRICE T ROWE ASSOCIATES INC /MD/ removed 407,816 shares (-26.6%) from their portfolio in Q2 2026, for an estimated $108,772,683

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ASND Price Targets

Multiple analysts have issued price targets for $ASND recently. We have seen 7 analysts offer price targets for $ASND in the last 6 months, with a median target of $326.0.

Here are some recent targets:

Luca Issi from RBC Capital set a target price of $280.0 on 07/07/2026
Eric Joseph from Citigroup set a target price of $355.0 on 05/19/2026
Josh Schimmer from Evercore ISI Group set a target price of $329.0 on 05/15/2026
Eliana Merle from Barclays set a target price of $345.0 on 05/11/2026
Derek Archila from Wells Fargo set a target price of $326.0 on 05/08/2026
Tazeen Ahmad from B of A Securities set a target price of $292.0 on 04/16/2026
Yun Zhong from Wedbush set a target price of $273.0 on 04/09/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.